The Cost of Prematurity: Quantification by Gestational Age and Birth Weight

  title={The Cost of Prematurity: Quantification by Gestational Age and Birth Weight},
  author={William M. Gilbert and Thomas S. Nesbitt and Beate H. Danielsen},
  journal={Obstetrics \& Gynecology},

Tables from this paper

Incremental Cost of Prematurity by Week of Gestational Age

Infants born at 25 to 37 weeks incur significantly higher birth hospitalization costs and experience significantly more health care utilization during the initial year of life, increasing progressively for each decreasing week of gestation, when compared with term infants.

Hospital costs and quality of life during 4 years after very preterm birth.

The cost per QALY in this patient group is at an acceptable level by 4 years of age because the initial hospital care episode accounted for most of the costs, and the cost perQALY will decrease with each additional follow-up year.

Shorter hospital stay for moderately preterm infants

Between 1983 and 2002, maternal age and use of nasal continuous positive airway pressure increased, use of antibiotics and mechanical ventilation decreased, whereas distributions for gestational age, birthweight, gender, smallness for gestations, low Apgar score or incidence of respiratory distress syndrome did not change.

Preterm Birth–Associated Cost of Early Intervention Services: An Analysis by Gestational Age

Compared with their term counterparts, preterm infants incurred higher early intervention costs, and costs that are associated with early childhood developmental services must be included when considering the long-term costs of prematurity.

Late Preterm Infants: Birth Outcomes and Health Care Utilization in the First Year

LPIs are at increased risk of poor health-related outcomes during their birth hospitalization and of increased health care utilization during their first year.

Cost of Hospitalization for Preterm and Low Birth Weight Infants in the United States

Costs per infant hospitalization were highest for extremely preterm infants, although the larger number of moderately preterm/low birth weight infants contributed more to the overall costs, suggesting that major infant and pediatric cost savings could be realized by preventing preterm birth.

Neonatal Outcomes of Late-Preterm Birth Associated or Not with Intrauterine Growth Restriction

It is shown that late- preterm IUGR infants present a significantly higher risk of neonatal complications when compared to late-preterm AGA infants.

Preterm birth in Sweden: What are the average lengths of hospital stay and the associated inpatient costs?

Estimates of the first‐year length of stay and inpatient costs of Swedish infants admitted for neonatal care by week of gestation and by birthweight and that of mothers of full‐term infants during the ante‐ and postpartum period are provided.

Determinants of morbidity in late preterm infants.

Cost of morbidities in very low birth weight infants.




A United States National Reference for Fetal Growth

A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants.

Preliminary evidence justifies further trials, but that further work is needed before any new routine procedure is established, as there may be an increased risk of fetal death in pregnancies complicated by severe hypertensionedema-proteinuria syndromes and treated with betamethasone.

The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials

Data from 12 controlled trials show that corticosteroids reduce the occurrence of respiratory distress syndrome overall and in all the subgroups of trial participants that were examined, and the available data on long‐term follow-up suggest that the short‐term beneficial effects of cortiosteroids may be reflected in reduced neurological morbidity in the longer term.

Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes.

Antenatal corticosteroid therapy is indicated for women at risk of premature delivery with few exceptions and will result in a substantial decrease in neonatal morbidity and mortality, as well as substantial savings in health care costs.

Received in revised form April 10

    Address correspondence to: William M